{"id":278,"date":"2026-10-09T00:32:18","date_gmt":"2026-10-09T00:32:18","guid":{"rendered":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/?post_type=product&#038;p=278"},"modified":"2026-10-09T00:32:21","modified_gmt":"2026-10-09T00:32:21","slug":"cjc-1295-no-dac-ipamorelin","status":"publish","type":"product","link":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/product\/cjc-1295-no-dac-ipamorelin\/","title":{"rendered":"CJC-1295 (no DAC) \/ Ipamorelin"},"content":{"rendered":"<section id=\"product-overview\" class=\"ma-section\">\n<h2>What is CJC-1295 No DAC &amp; Ipamorelin?<\/h2>\n<p>The <strong>CJC-1295 No DAC &amp; Ipamorelin<\/strong> dual reference complex (commonly designated as <em>CJC 1295 ipamorelin, CJC-1295\/ipamorelin, CJC\/IPA, or IPA\/CJC<\/em>) is a precision-formulated peptide combination engineered to investigate dual-receptor somatotropic axis activation. The combination pairs <strong>CJC-1295 No DAC<\/strong>(also known as Modified GRF 1-29), a 29-amino-acid synthetic analogue of endogenous Growth Hormone Releasing Hormone (GHRH), with <strong>Ipamorelin<\/strong>, a selective pentapeptide growth hormone secretagogue.<\/p>\n<p>When evaluated independently, each peptide targets a distinct, complementary receptor class on pituitary somatotropes. When studied in combination, the <strong>CJC 1295 peptide<\/strong> complex produces a pronounced synergistic response, elevating growth hormone synthesis and secretion significantly beyond the calculated additive output of either compound alone, while maintaining complete receptor selectivity.<\/p>\n<p>Batch-verified for high analytical purity at Chicago BioResearch Labs, the CJC-1295 No DAC &amp; Ipamorelin blend is offered in two standardized laboratory formats:<\/p>\n<ul>\n<li>5MG\/5MG dual lyophilized reference powder vial complex<\/li>\n<li>10MG\/10MG dual lyophilized reference powder vial complex<\/li>\n<\/ul>\n<p>Laboratories researching pituitary secretagogue kinetics, intracellular signal amplification, and neuro-endocrine feedback loops evaluate this blend alongside complementary secretagogues available on the site, such as Tesamorelin, Sermorelin, GHRP-2, and GHRP-6.<\/p>\n<\/section>\n<p>&nbsp;<\/p>\n<section id=\"chemical-molecular-data\" class=\"ma-section\">\n<h2>Chemical and Molecular Data<\/h2>\n<div class=\"ma-table-container\">\n<table class=\"ma-spec-table\" summary=\"Chemical and molecular specifications for CJC-1295 No DAC &amp; Ipamorelin\">\n<tbody>\n<tr>\n<th scope=\"row\">Compound Complex<\/th>\n<td>CJC-1295 No DAC (Modified GRF 1-29) + Ipamorelin Blend<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Quantity \/ Formats Offered<\/th>\n<td>5MG\/5MG Lyophilized Powder Vials<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">CJC-1295 No DAC Sequence<\/th>\n<td><code>Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH<sub>2<\/sub><\/code><\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Ipamorelin Sequence<\/th>\n<td><code>Aib-His-D-2-Nal-D-Phe-Lys-NH<sub>2<\/sub><\/code><\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">CAS Numbers<\/th>\n<td><a title=\"PubChem CJC-1295 Entry\" href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/863288-34-0\" target=\"_blank\" rel=\"noopener noreferrer\">863288-34-0<\/a> (CJC-1295 No DAC) | <a title=\"PubChem Ipamorelin Entry\" href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/170851-70-4\" target=\"_blank\" rel=\"noopener noreferrer\">170851-70-4<\/a> (Ipamorelin)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Chemical Formulas<\/th>\n<td>C<sub>152<\/sub>H<sub>252<\/sub>N<sub>44<\/sub>O<sub>42<\/sub> (CJC-1295) | C<sub>38<\/sub>H<sub>49<\/sub>N<sub>9<\/sub>O<sub>5<\/sub> (Ipamorelin)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Molecular Weights<\/th>\n<td>3367.20 g\/mol (CJC-1295 No DAC) | 711.86 g\/mol (Ipamorelin)<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">IUPAC Name (CJC-1295 No DAC)<\/th>\n<td>Modified Growth Hormone Releasing Factor (1-29) amide<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">InChIKey (Ipamorelin)<\/th>\n<td>InChIKey=HUPFGBLSBRKMLB-UHFFFAOYSA-N<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n<p>&nbsp;<\/p>\n<section id=\"mechanisms-of-action\" class=\"ma-section\">\n<h2>What are the Mechanisms of Action?<\/h2>\n<p>The biochemical pathways and cellular targets of the <strong>CJC-1295 ipamorelin<\/strong> complex in laboratory research include:<\/p>\n<ul>\n<li><strong>GHRH Receptor Activation (G<sub>s<\/sub>-cAMP Pathway):<\/strong> CJC-1295 No DAC selectively binds the Growth Hormone Releasing Hormone (GHRH) receptor on somatotrope cell membranes. Receptor occupancy activates stimulatory G-protein (G<sub>s<\/sub>), triggering adenylate cyclase to convert ATP into cyclic AMP (cAMP). Elevated intracellular cAMP activates Protein Kinase A (PKA), upregulating growth hormone gene transcription and priming secretory vesicles.<\/li>\n<li><strong>GHS-R<sub>1a<\/sub> Activation (G<sub>q\/11<\/sub>-Ca<sup>2+<\/sup> Pathway):<\/strong> Ipamorelin binds the Growth Hormone Secretagogue Receptor (GHS-R<sub>1a<\/sub> \/ Ghrelin receptor) with high nanomolar affinity. This activates the G<sub>q\/11<\/sub> protein subunit, stimulating Phospholipase C (PLC) to cleave membrane lipids into inositol trisphosphate (IP<sub>3<\/sub>) and diacylglycerol (DAG). IP<sub>3<\/sub> triggers rapid calcium (Ca<sup>2+<\/sup>) release from the endoplasmic reticulum into the cytosol.<\/li>\n<li><strong>Dual-Receptor Somatotrope Synergy:<\/strong> Simultaneous activation of the G<sub>s<\/sub>\/cAMP cascade (CJC-1295) and the G<sub>q\/11<\/sub>\/Ca<sup>2+<\/sup> cascade (Ipamorelin) creates intracellular signal amplification. The concurrent rise in PKA phosphorylation and cytosolic Ca<sup>2+<\/sup> drives exocytosis of primed GH storage granules, resulting in a robust, natural pulsatile secretion pattern.<\/li>\n<\/ul>\n<\/section>\n<p>&nbsp;<\/p>\n<section id=\"clinical-trials\" class=\"ma-section\">\n<h2>What do Preclinical &amp; Academic Studies Show for CJC-1295 &amp; Ipamorelin?<\/h2>\n<p id=\"does-cjc-ipamorelin-work\">When evaluating research efficacy and published scientific literature for <em>CJC 1295 ipamorelin<\/em> reference materials:<\/p>\n<ul>\n<li><strong>Somatotrope Secretagogue Selectivity (PubMed):<\/strong> Landmark pharmacological studies cataloged on <a title=\"PubMed Ipamorelin Study\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/9839330\/\" target=\"_blank\" rel=\"noopener noreferrer\">PubMed (PMID: 9839330)<\/a> demonstrate that Ipamorelin stimulates growth hormone release with extreme selectivity, displaying zero affinity for ACTH, cortisol, prolactin, or aldosterone receptors in pituitaries.<\/li>\n<li><strong>GHRH Receptor Kinetics &amp; Peptide Stability (PMC):<\/strong> Comprehensive biomedical reviews archived in <a title=\"PMC GHRH Research\" href=\"https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8540866\/\" target=\"_blank\" rel=\"noopener noreferrer\">PMC (PMC8540866)<\/a> confirm that tetrasubstitution in Modified GRF 1-29 (CJC-1295 No DAC) prevents rapid dipeptidyl peptidase-IV (DPP-IV) enzymatic cleavage, maintaining high biological potency in somatotrope cell models.<\/li>\n<li><strong>Chemical Profiling &amp; Identification (PubChem):<\/strong> Official structural characterization maintained on <a title=\"PubChem CJC-1295 Database\" href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/863288-34-0\" target=\"_blank\" rel=\"noopener noreferrer\">PubChem<\/a> verifies the molecular mass, amino acid sequences, and mass spectrometry profiles of CAS 863288-34-0 (CJC-1295) and CAS 170851-70-4 (Ipamorelin).<\/li>\n<\/ul>\n<\/section>\n<p>&nbsp;<\/p>\n<section id=\"comparisons\" class=\"ma-section\">\n<h2>How does the CJC\/IPA blend compare to individual peptides?<\/h2>\n<p>To evaluate receptor crosstalk, signal transduction kinetics, and secretagogue potency, researchers compare the CJC-1295 No DAC &amp; Ipamorelin complex against standalone reference peptides available at Chicago BioResearch Labs:<\/p>\n<div class=\"ma-table-container\">\n<table class=\"ma-comparison-table\" summary=\"Comparison between CJC\/IPA Blend, CJC-1295 No DAC, Ipamorelin, and Tesamorelin\">\n<thead>\n<tr>\n<th scope=\"col\">Compound \/ Reference<\/th>\n<th scope=\"col\">Primary Receptor Target<\/th>\n<th scope=\"col\">Core Mechanism of Action<\/th>\n<th scope=\"col\">Research Focus &amp; Profile<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<th scope=\"row\">CJC-1295 No DAC &amp; Ipamorelin Blend<\/th>\n<td>Dual GHRH Receptor &amp; GHS-R<sub>1a<\/sub> Agonist<\/td>\n<td>Simultaneously activates G<sub>s<\/sub>\/cAMP and G<sub>q\/11<\/sub>\/Ca<sup>2+<\/sup>pathways, producing synergistic GH pulse amplification<\/td>\n<td>Focuses on dual-pathway somatotrope synergy, physiological GH pulse modeling, and maximal secretagogue receptor cross-talk<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">CJC-1295 No DAC (Mod GRF 1-29)<\/th>\n<td>GHRH Receptor (G<sub>s<\/sub>-Coupled)<\/td>\n<td>Stimulates adenylate cyclase to elevate cAMP and PKA, priming GH gene transcription and vesicle synthesis<\/td>\n<td>Focuses on isolated GHRH receptor kinetics, enzymatic resistance against DPP-IV, and baseline GH transcription research<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Ipamorelin<\/th>\n<td>GHS-R<sub>1a<\/sub> Ghrelin Receptor (G<sub>q\/11<\/sub>-Coupled)<\/td>\n<td>Triggers Phospholipase C (PLC) to mobilize cytosolic Ca<sup>2+<\/sup>, driving exocytosis of stored GH granules<\/td>\n<td>Focuses on highly selective ghrelin receptor agonism without off-target cortisol, ACTH, or prolactin elevation<\/td>\n<\/tr>\n<tr>\n<th scope=\"row\">Tesamorelin<\/th>\n<td>N-Terminal Trans-3-Hexenooyl GHRH Analogue<\/td>\n<td>Binds GHRH receptors with high stability, modulating hepatic IGF-1 transcription and lipid metabolism<\/td>\n<td>Focuses on high-affinity GHRH receptor signaling, hepatic gene expression, and visceral lipid metabolic modeling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/section>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The CJC-1295 (No DAC) &amp; Ipamorelin blend combines a tetrasubstituted Growth Hormone Releasing Hormone (GHRH) receptor agonist (Modified GRF 1-29) with a highly selective pentapeptide Growth Hormone Secretagogue Receptor (GHS-R<sub>1a<\/sub>) agonist. By simultaneously activating G<sub>s<\/sub>-coupled adenylate cyclase\/cAMP and G<sub>q\/11<\/sub>-coupled intracellular calcium (Ca2+) cascades in anterior pituitary somatotropes, the CJC\/IPA blend generates synergistic, pulsatile growth hormone secretion without stimulating baseline ACTH, cortisol, or prolactin release.<\/p>\n","protected":false},"featured_media":119,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[19],"product_tag":[],"class_list":["post-278","product","type-product","status-publish","has-post-thumbnail","product_cat-uncategorized","first","instock","shipping-taxable","purchasable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/product\/278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/comments?post=278"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/media\/119"}],"wp:attachment":[{"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/media?parent=278"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/product_brand?post=278"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/product_cat?post=278"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/ecomprohub.com\/chicagobioresearchlab\/wp-json\/wp\/v2\/product_tag?post=278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}